




16 March 2026

Re: Upphörandeuppmanning gällande marknadsföring av Mounjaro (letter dated 2 March 2026)

Thank you for reaching out to us directly on this matter. We appreciate the open approach and would very much like to continue this type of direct communication between our companies.

We have carefully reviewed your letter of 2 March 2026 and the points raised therein, and we provide the following response.

We acknowledge the recent approval of the Wegovy 7.2 mg maintenance dose. At the same time, SURMOUNT-5 is, and remains, the only head-to-head clinical trial directly comparing semaglutide and tirzepatide for the treatment of obesity. The study evaluated the maximum tolerated doses of both therapies — semaglutide up to 2.4 mg and tirzepatide up to 15 mg — as approved by regulators and commercially available at the time the trial was designed and conducted, and the results have been published in The New England Journal of Medicine. This study constitutes the principal comparative evidence base available to healthcare professionals when evaluating these treatments. The validity and relevance of SURMOUNT-5 as a head-to-head trial are not diminished by the subsequent approval of a higher semaglutide dose.

With regard to the price comparison referenced in your letter, we note that the materials clearly identify the specific doses to which the pricing applies. While pricing tables are provided to inform of cost context and should not be read to imply clinical efficacy or dosing equivalence, our objective is to ensure a clear and balanced presentation. Accordingly, where pricing appears alongside clinical information we make the dosing context for each product clear.

We will, however, review our materials in these respects, including to ensure that they accurately reflect the current marketing authorisation status of the products concerned and fact that semaglutide 2.4 mg is no longer the highest authorised maintenance dose of Wegovy.

We trust that the above demonstrates our commitment to responsible and compliant communication. We remain open to further dialogue and would welcome the opportunity to discuss these matters directly should you wish to do so.

Kind regards,


Eli Lilly Sweden AB